Keyphrases
Mirtazapine
100%
Nausea-vomiting
100%
Nausea
85%
Vomiting in Pregnancy
57%
Pregnant Women
42%
Hyperemesis Gravidarum
28%
Tolerability
28%
Hyperemesis
14%
Ondansetron
14%
Vomiting
14%
Rapid Reduction
14%
Pregnant Women's Experiences
14%
Need for Treatment
14%
Mid-pregnancy
14%
Pregnancy Symptoms
14%
Emesis
14%
Direct Treatment
14%
Remeron
14%
Condition-dependent
14%
Randomized Controlled Trial
14%
Treatment Research
14%
Clinical Trials
14%
Daily Functioning
14%
Pharmacogenetics
14%
Phase II Study
14%
Structural Brain Changes
14%
Physiologic
14%
Repurposing
14%
Small-for-gestational Age
14%
Trial Planning
14%
Drug pipeline
14%
Weight Loss
14%
Therapeutic Potential
14%
Third Trimester
14%
NICHD
14%
Lactating Women
14%
Developmental Issues
14%
Birth Defects
14%
Causes of Hospitalization
14%
Quality of Life
14%
Plasma Concentration
14%
Dosing Regimen
14%
Preterm Birth
14%
Cancer Chemotherapy
14%
Severe Disease
14%
Serotonin Receptors
14%
Reproductive Outcome
14%
Pharmacology, Toxicology and Pharmaceutical Science
Mirtazapine
100%
Nausea
100%
Nausea and Vomiting
62%
Tolerability
25%
Hyperemesis Gravidarum
25%
Clinical Trial
12%
Pharmacogenetics
12%
Cancer Chemotherapy
12%
Randomized Controlled Trial
12%
Zofran
12%
Repurposing
12%
Premature Labor
12%
Serotonin Receptor
12%
Small for Date Infant
12%
Congenital Malformation
12%
Receptor
12%